Dr. Reddy’s Laboratories on Friday (September 18, 2026) entered into an exclusive distribution agreement with Takeda Pharmaceutical Company to promote and distribute its dengue vaccine, QDENGA , in India’s private market for pediatric and adult vaccination.
While Dr. V. Ramana, CEO, Global Generics, Dr. Reddy’s Laboratories.
Subject to local regulatory processes, the vaccine is expected to be available in the first half of 2027. The vaccine received marketing authorisation by the Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years, Dr. QDENGA, a live-attenuated tetravalent vaccine, aims to strengthen dengue prevention and management by providing broad immune coverage across all four circulating dengue virus serotypes (DENV-1 to DENV-4).
Reddy’s said in a press release. Administered as a two-dose regimen given three months apart, it is India’s first approved dengue vaccine , according to the release. Reddy’s will exclusively manage private-market distribution, disease awareness, and healthcare professional engagement, Takeda will retain rights for the public market, legal ownership, and overall medical and brand oversight, it said. “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape,” said M.
